Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00380783

Enrollment

Registered

2006-09-26

Start date

2006-10-31

Completion date

2007-03-31

Last updated

2011-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystitis, Interstitial

Brief summary

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis

Interventions

DRUGAGN 203818

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of painful bladder syndrome/interstitial cystitis * Moderate or severe bladder pain

Exclusion criteria

* Any other uncontrolled disease * Pregnant or nursing females

Design outcomes

Primary

Measure	Time frame
Reduction in daily pain scores	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026